Efficacy and safety of ivonescimab in non-small cell lung cancer: a systematic review and meta-analysis of emerging clinical data

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2026-02-03
DOI
https://doi.org/10.3389/fphar.2026.1770637
Citations
2
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
48.39

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Efficacy and safety of ivonescimab in non-small cell lung cancer: a systematic review and meta-analysis of emerging clinical data

Youran Dai, Qingyan Chen, Chenwei Xiao, Zerun Cheng et al.
2 citations
Frontiers in Pharmacology
Cancer Immunotherapy and Biomarkers
48.39
article

Efficacy and safety of ivonescimab in non-small cell lung cancer: a systematic review and meta-analysis of emerging clinical data

Youran Dai, Qingyan Chen, Chenwei Xiao, Zerun Cheng, Ruiqing Bo, Guofeng Pan, Liang Wang
article en
2 citations

Abstract

No abstract available for this paper.
Frontiers in PharmacologyVol. 17
Zhejiang Chinese Medical University (CN), Beijing University of Chinese Medicine (CN), Beijing Shijitan Hospital (CN)
Beijing Municipal Health Commission
Good health and well-being
Openalex Percentile: Top 0%
Cancer Immunotherapy and Biomarkers
48.39
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.